Outcomes of patients with advanced stage ovarian cancer with intestinal metastasis
- PMID: 29192414
- DOI: 10.5603/GP.a2017.0098
Outcomes of patients with advanced stage ovarian cancer with intestinal metastasis
Abstract
Objectives: The aim of this study is to evaluate the results of advanced stage (stage IIIB-IVB) ovarian cancer (OC) patients with intestinal metastasis, and to investigate the factors that affect survival.
Material and methods: Patients who underwent cytoreductive surgery (CS) for FIGO stage IIIB-IVB OC with metastasis in the intestinal system, at Tepecik Research and Treatment Hospital between 2008-2014, were analyzed retrospectively. Patients with borderline ovarian tumor; those who had previously undergone radiation therapy and/or hysterectomy and patients having secondary or tertiary cytoreduction were excluded and 49 patients were included and analyzed in this study. Hysterectomy, bilateral salpingo-oopherectomy, pelvic and para-aortic lymph node sampling, resection of bulky lymph nodes and omentectomy were performed. Optimal cytoreduction was accepted as that which left residual tumor ≤ one cm maximum size.
Results: The risk factors affecting OS interval were investigated according to Cox' regression analysis. Optimality of the primary CS (P = 0.008 and HR = 5.202) and cancer stage (P = 0.016 and HR = 6.083) were found to be statistically significant factors.
Conclusions: Achieving optimal CS is the most important aim for the general surgeon carrying out an intestinal resection procedure. Although resection procedures are superior in providing the desired optimal results when compared to excision surgery, their higher complication rates and subsequent lower quality of life must be taken into consideration when choosing either resection or excision methods; surgical intervention should always be kept to the minimum possible.
Keywords: gynecologic surgical procedures; intestinal neoplasms; ovarian neoplasms.
Similar articles
-
Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer.Eur J Surg Oncol. 2016 Mar;42(3):383-90. doi: 10.1016/j.ejso.2015.12.001. Epub 2015 Dec 17. Eur J Surg Oncol. 2016. PMID: 26725211
-
Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.Eur J Surg Oncol. 2013 Jul;39(7):786-91. doi: 10.1016/j.ejso.2013.02.006. Epub 2013 Mar 13. Eur J Surg Oncol. 2013. PMID: 23490332
-
[Clinical observation of partial pancreatectomy as part of primary cytoreductive surgery in advanced epithelial ovarian cancer].Zhonghua Fu Chan Ke Za Zhi. 2016 May 25;51(5):361-5. doi: 10.3760/cma.j.issn.0529-567X.2016.05.008. Zhonghua Fu Chan Ke Za Zhi. 2016. PMID: 27256444 Chinese.
-
Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.Oncology. 2016;91(4):211-216. doi: 10.1159/000447743. Epub 2016 Aug 3. Oncology. 2016. PMID: 27487241 Review.
-
Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.Curr Treat Options Oncol. 2016 Jan;17(1):1. doi: 10.1007/s11864-015-0380-2. Curr Treat Options Oncol. 2016. PMID: 26714493 Review.
Cited by
-
Preoperative colonoscopy in patients with a supposed primary ovarian cancer.Medicine (Baltimore). 2019 Mar;98(12):e14929. doi: 10.1097/MD.0000000000014929. Medicine (Baltimore). 2019. PMID: 30896654 Free PMC article.
-
Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway.Braz J Med Biol Res. 2020;53(6):e8885. doi: 10.1590/1414-431x20208885. Epub 2020 May 8. Braz J Med Biol Res. 2020. Retraction in: Braz J Med Biol Res. 2025 Jun 16;58:e8885retraction. doi: 10.1590/1414-431X2025e8885retraction. PMID: 32401925 Free PMC article. Retracted.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical